Humacyte Financials - Benzinga

Humacyte Inc

HUMANASDAQ

Trade with Public

Trade with Public

$0.6422

-0.0392-5.75%

At close: Aug 21, 5:00 PM EST

$0.6649

0.02273.53%

After Hours: 7:57 PM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Humacyte Financials

Humacyte (HUMA) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Humacyte Q2 EPS $(0.16) Misses $(0.10) Estimate, Sales $406.000K Miss $1.116M Estimate

Humacyte (NASDAQ:HUMA) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.10) by 60 percent. This is a 33.33 percent increase over losses of $(0.24) per share from the same

Benzinga Newsdesk

Earnings Scheduled For May 13, 2026

Benzinga Insights

PRO
Humacyte Q1 EPS $(0.09) Beats $(0.11) Estimate, Sales $495.000K Miss $1.455M Estimate

Humacyte (NASDAQ:HUMA) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.11) by 18.18 percent. This is a 10 percent increase over losses of $(0.10) per share from the same

Benzinga Newsdesk

Earnings Scheduled For March 27, 2026

Benzinga Insights

PRO
Humacyte Q4 EPS $(0.13), Inline, Sales $467.000K Miss $1.343M Estimate

Benzinga Newsdesk

PRO
Humacyte Q3 EPS $(0.11) Beats $(0.16) Estimate, Sales $753.000K Miss $922.333K Estimate

Benzinga Newsdesk